NanoRepro AG

Equities

NN6

DE0006577109

Medical Equipment, Supplies & Distribution

Market Closed - Xetra Other stock markets 11:36:10 2024-04-26 am EDT			5-day change	1st Jan Change
1.845 ^EUR	-0.27%		+6.03%	-7.52%

2023	NanoRepro AG Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	NanoRepro AG commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 29, 2022.	CI

NanoRepro AG Reports Earnings Results for the Half Year Ended June 30, 2023

October 31, 2023 at 03:04 pm EDT

NanoRepro AG reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 1.39 million compared to EUR 25.95 million a year ago. Net loss was EUR 2.65 million compared to net income of EUR 0.204484 million a year ago.

Latest news about NanoRepro AG

NanoRepro AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-31	CI
NanoRepro AG commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 29, 2022.	23-05-21	CI
NanoRepro AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-04	CI
NanoRepro AG Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-27	CI
NanoRepro AG Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-13	CI
NanoRepro to Supply 41 Million Rapid COVID-19 Antigen Tests to Viromed	21-11-24	MT
NanoRepro AG Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-23	CI
NanoRepro : Secures CE Mark on Two SARS-CoV-2 Tests	21-06-14	MT
Nanorepro Ag Reports Earnings Results for the Full Year Ended December 31, 2020	21-05-20	CI
NanoRepro AG announced that it has received €0.9 million in funding	17-11-05	CI
NanoRepro AG Signs Distribution Agreement for Romania, Moldova	15-06-18	CI
NanoRepro AG (DB:NN6) acquired brand alphabiol from Alphablom AG.	15-03-03	CI

Chart NanoRepro AG

Duration

Period

More charts

Company Profile

Nanorepro AG is a Germany-based company active in the biotechnology sector. The Company is engaged in the research of stem cells, which are used in the medical treatment due to their ability to self-renew and differentiate to a range of specialized cell types. Nanorepro AG gathers samples of patientsâ stem cells and stores them for the future use. Its portfolio also comprises OTC rapid diagnostic tests, such as OvuQUICK, an ovulation test for women; GraviQUICK, a pregnancy test; MenoQUICK, a menopause test; VagiQUICK, a vaginal yeast test; GlutenCHECK, a test to detect celiac disease; CholesterinCHECK, a test to measure the level of total cholesterol, HDL and LDL, as well as FertiQUICK, a fertility test for men.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NANOREPRO AG	-7.52%	25.37M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution